MEDCAMP SA

  • Market Cap: Micro Cap
  • Industry: Real Estate Development
  • ISIN: PLTCHPR00019
PLN
0.76
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About MEDCAMP SA stock-summary
stock-summary
MEDCAMP SA
Real Estate Development
Medcamp SA, formerly T2 Investment SA, is a Poland-based company engaged in the real estate operations. The Company is involved in the acquisition, management, redevelopment and upgrade, as well as rental and sale of commercial properties, including office areas and warehouses. In addition, the Company is involved in long-term investments in construction and real estate entities. It conducts rental and redevelopment projects, such as Poznan, Jasielska; Poznan, Komorniki; Poznan, Jasielska, Inkubator; Szamotuly, Dworcowa; among others. The Company aims to build a research and development center in Poznan, specializing in such areas as personalized medicine, genetics, genomics and bioinformatics, supported by artificial intelligence, The Company operates through subsidiaries, including T2 Inkubator Sp z o o, T2 Szamotuly Sp z o o, Polskie Centrum Badan i Rozwoju Sp z o o, among others. The majority shareholder of the Company is Moonrock Enterprise SA.
Company Coordinates stock-summary
Company Details
Ul. Jeleniogorska 16 C/3 , POZNAN None : 60-179
stock-summary
Tel: 48 61 6648000
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 0 Foreign Institutions (0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Andrzej Dulnik
Secretary of the Supervisory Board
Prof. Dr. Tomasz Banasiewicz
Member of the Supervisory Board
Mr. Bogdan Kasprzyk
Member of the Supervisory Board
Mr. Mariusz Koitka
Member of the Supervisory Board
Mr. Dariusz Kojat
Member of the Supervisory Board
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
(Quarterly Results - Mar 2025)
Net Profit:
0 Million
stock-summary
Industry

Real Estate Development

stock-summary
Market cap

PLN 20 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-999,999.00

stock-summary
Return on Equity

-171.66%

stock-summary
Price to Book

20.14